Industries · Cell & Gene Therapy
OMICS4 runs the molecular characterization behind your cell engineering and gene therapy programs (transcriptomic profiling, vector and expression quantification, and QC), bookable in-house and through our partner network.
Overview
Engineering a cell or gene therapy product demands tight molecular characterization at every stage. OMICS4 supports these programs with transcriptomic profiling and vector expression analysis run in-house, with specialist vector and cell-therapy expertise from our partner CTI Biotech available where a project calls for it.
OMICS4 capabilities
Bulk RNA-seq framing before/after transduction or gene editing.
Molecular readouts on vector behavior across development stages.
QC scoped to your process development and release milestones.
Custom pipelines built per construct, not a generic template, delivered by GenXMap's Computational Biology & AI layer on top of our wet-lab data.
How OMICS4 adapts
No two programs run the same workflow. Here is how OMICS4 fits into what you already have in place.
Your process runs under GMP-adjacent process development, with strict batch and lot traceability.
Every sample is tracked with your internal lot IDs end-to-end; reports are structured to slot directly into your batch records.
Vector and cell line constructs vary program to program, so off-the-shelf pipelines don't fit.
Pipelines are reconfigured per construct (vector backbone, promoter, edit site) rather than run through a generic RNA-seq template.
Development timelines are milestone-driven: IND-enabling studies, potency assay lock, tech transfer.
Turnaround and QC checkpoints are scheduled against your milestone calendar, not a fixed lab queue.
Data needs to feed into your existing ELN/LIMS and regulatory documentation.
Deliverables are exported in the format your team already uses: CSV/Excel for LIMS import, PDF summaries for regulatory binders.
Have a project in this space?